Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging Tau and Amyloid in Blast-Related mTBI
NCT05337774Phase 1Terminated
- Sponsor
- Life Molecular Imaging
- Start
- Jun 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-PI-2620 in traumatic brain injury (TBI), sponsored by Life Molecular Imaging. Primary endpoints: Tau deposition in the brain at 1 day and Amyloid deposition in the brain at 1 day. Started Jun 2021; status: terminated.
02
Drugs
18F-PI-2620
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05337774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337774.